FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 631 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... December 13, 2023 BRAF Inhibitor and Rituximab for the Management of Refractory or Relapsed... May 19, 2021 First-of-its-kind app for patients on clinical trials being piloted by Cancer... November 28, 2022 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 Load more HOT NEWS New on NCI Websites for July 2019 “The power of science”: HPV vaccine proven to dramatically reduce cervical... Study Offers Insights on Health Problems among AYA Cancer Survivors 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic...
